[
  {
    "ts": "2025-08-26T14:00:16+00:00",
    "headline": "Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance A Reflection Of Its Financial Health?",
    "summary": "Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 4.2% over the past month. Since...",
    "url": "https://finance.yahoo.com/news/abbott-laboratories-nyse-abt-stocks-140016713.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a231c34e-3c96-3bb7-bf55-7f9fc80f6285",
      "content": {
        "id": "a231c34e-3c96-3bb7-bf55-7f9fc80f6285",
        "contentType": "STORY",
        "title": "Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance A Reflection Of Its Financial Health?",
        "description": "",
        "summary": "Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 4.2% over the past month. Since...",
        "pubDate": "2025-08-26T14:00:16Z",
        "displayTime": "2025-08-26T14:00:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7zJOBZ6wPnYKbKPRmWh.qQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sc9EgsXKjWnUzlOQpxWhqQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-laboratories-nyse-abt-stocks-140016713.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-laboratories-nyse-abt-stocks-140016713.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-26T09:13:20+00:00",
    "headline": "Abbott’s Esprit BTK System gains CE mark for PAD treatment",
    "summary": "The stent is engineered to keep arteries open, deliver everolimus for vessel healing, and gradually dissolve over time.",
    "url": "https://www.medicaldevice-network.com/news/abbott-esprit-btk-system-ce-mark-pad/",
    "source": "Medical Device Network",
    "provider": "yfinance",
    "raw": {
      "id": "f2fbceea-e6ca-3ed0-9a77-3726d7568921",
      "content": {
        "id": "f2fbceea-e6ca-3ed0-9a77-3726d7568921",
        "contentType": "STORY",
        "title": "Abbott’s Esprit BTK System gains CE mark for PAD treatment",
        "description": "",
        "summary": "The stent is engineered to keep arteries open, deliver everolimus for vessel healing, and gradually dissolve over time.",
        "pubDate": "2025-08-26T09:13:20Z",
        "displayTime": "2025-08-26T09:13:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medical_device_network_744/7d499a629303a4ec20491cbe55d72af9",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "Abbott's Esprit BTK System receives European approval for below-knee PAD. Credit: Tada Images / Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9Wrya9cOIJ2UGrb65ktL1g--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medical_device_network_744/7d499a629303a4ec20491cbe55d72af9.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n0jzemNuVxdGBZCYQghkpQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medical_device_network_744/7d499a629303a4ec20491cbe55d72af9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Medical Device Network",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medicaldevice-network.com/news/abbott-esprit-btk-system-ce-mark-pad/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-esprit-btk-system-gains-091320340.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-26T06:29:00+00:00",
    "headline": "Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment",
    "summary": "Abbott (NYSE: ABT), the global healthcare leader, has received regulatory approval for the first denosumab biosimilar in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone loss. With the introduction of Abbott's denosumab biosimilar in Thailand, this advanced biologic treatment will be more affordable and accessible for the estimated 3 million people suffering from osteoporosis and bone-disease related illness in the country.1,2,3",
    "url": "https://finance.yahoo.com/news/abbott-receives-regulatory-approval-first-062900799.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "83372231-3273-36b5-bfb3-7ea5bfe66ac6",
      "content": {
        "id": "83372231-3273-36b5-bfb3-7ea5bfe66ac6",
        "contentType": "STORY",
        "title": "Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment",
        "description": "",
        "summary": "Abbott (NYSE: ABT), the global healthcare leader, has received regulatory approval for the first denosumab biosimilar in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone loss. With the introduction of Abbott's denosumab biosimilar in Thailand, this advanced biologic treatment will be more affordable and accessible for the estimated 3 million people suffering from osteoporosis and bone-disease related illness in the country.1,2,3",
        "pubDate": "2025-08-26T06:29:00Z",
        "displayTime": "2025-08-26T06:29:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/bc8e208c13d4d64f6346d09e388247f5",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X3r1DtSaraaegm6bJcoW6Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/bc8e208c13d4d64f6346d09e388247f5.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ImANO2ePWrbMdul.nBPlRQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/bc8e208c13d4d64f6346d09e388247f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-receives-regulatory-approval-first-062900799.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-receives-regulatory-approval-first-062900799.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]